The Surface Covering Ability of Albumin
The surface adsorption qualities of albumin mean that it is predisposed to coat both hydrophobic and hydrophilic surfaces [1]. In the past, albumin has been utilized to coat surfaces of medical instruments to expand their biocompatibility.
Studies have found that spontaneously formed albumin coverage is in the order of a single albumin molecule deep with only 1-2 mg of albumin necessary to coat 1 m² of surface. This characteristic can be beneficial in low dose high potency drugs, where the dose could be challenging to manage because of its surface adsorption during production, handling, and storage.
An additional benefit of albumin coating surfaces is hindrance of surface-induced unfolding and API aggregation events that can lead to loss of efficacy and safety issues.
Protection Against Surface Adsorption
Remaining attached over time, Recombumin® recombinant human albumin (rAlb) works to protect against drug adsorption due to its own adsorption to hydrophobic and hydrophilic surfaces. The coverage of the surface is generally accomplished in just a mono layer of Recombumin®.
This point is illustrated below by the increased recovery of drug from a vial when albumin is added to the formulation because of reduced surface adsorption of the protein TGF-β3 to the vial surface.
References
- Kowalcyzńska H.M., Nowak-Wyrzkowska M., Szczepankiewicz A.A., Dobkowski J., Dyda, M., Kamiński, J., Kolos R.; Albumin Adsorption on Unmodified and Sulfonated Polystyrene Surfaces, in Relation to Cell-Substratum Adhesion. Coll Surfaces Biointerfaces (2011) 84 536-544.
About Albumedix Ltd.
Too many people battle with diseases that keep them from living a full life. Healthcare professionals work hard every day to provide these people with better therapies. Together with partners, Albumedix utilize its albumin-based drug enhancing products and technologies to enable the development of more effective treatments.
With more than 30 years of experience, we are proud to be recognized as the world leader in recombinant human albumin products and technologies.
As the highest quality recombinant human albumin products ever developed, Albumedix enables the effective formulation of otherwise hard-to-stabilize drugs, cell therapies, and vaccines.
Our albumin-based technologies offer new ways of optimizing drug dosing and enhancing therapeutic performance by increasing the half-life, payload capacity, and tissue specific delivery of active pharmaceutical agents. This results in simpler treatment regimens, better performance, and, ultimately, improved patient outcomes.
Albumedix is headquartered in Nottingham, UK, with both research and large-scale manufacturing facilities. We are all committed to improving patient quality of life and are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.